Daniel Gold, PhD
President & Chief Executive Officer
Dr. Gold was appointed President & Chief Executive Officer in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that advanced the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor's degree in Biology from the University of California, Los Angeles.
Robert Mass, MD
Chief Medical Officer
Dr. Mass has more than 20 years of experience as a medical oncologist in both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of the non-sponsored clinical programs within the company’s oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval of all sponsored clinical programs across the company’s therapeutic portfolio. Previously he served as clinical science leader for Herceptin® from 1999 to 2002, Tarceva® from 2002 to 2003, and Avastin®, currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr. Mass earned his bachelor’s degree in economics from Tufts University and his medical degree from Oregon Health & Science University. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology.
Chief Financial Officer
Mr. Drazba joined as Chief Financial Officer in April 2017 with more than 25 years of financial management experience in the healthcare industry. Previously, he served as Vice President of Finance and Chief Financial Officer of Heron Therapeutics, a commercial-stage biotechnology company, from October 2013 to March 2017. From 2009 to 2012, he was Vice President of Finance and Chief Accounting Officer for ISTA Pharmaceuticals, a commercial-stage pharmaceutical company. ISTA Pharmaceuticals was acquired by Bausch + Lomb in June 2012. From 1992 to 2009, Mr. Drazba held various positions of increasing responsibility within Insight Health Corp., most recently as Senior Vice President and Chief Accounting Officer. He began his career at Arthur Andersen & Co., a public accounting firm. Mr. Drazba is a licensed Certified Public Accountant in California and received a B.A. degree in accounting from the University of San Diego.
David Urso, JD
Senior Vice President, Corporate Development & General Counsel
Mr. Urso joined MEI Pharma in March 2014 with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals, a privately held drug development company he co-founded in 2005. Previously, he was a Principal at Forward Ventures, where he was responsible for identifying and developing life science venture capital investments. Prior to joining Forward Ventures in 2002, Mr. Urso was Director of Corporate Development and Legal Affairs at DNA Sciences. Previously, he worked as an attorney in the corporate securities and licensing groups at Wilson Sonsini Goodrich & Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School. Mr. Urso received a J.D. from Harvard Law School and a bachelor's degree in Molecular Biology and Philosophy from Reed College.
Karen Potts, PhD
Senior Vice President, Regulatory Affairs
Dr. Potts joined as Senior Vice President, Regulatory Affairs in October 2014. Her career spans both the biotechnology and pharmaceutical industries, where she has led global regulatory teams to successfully facilitate the development, approval and life cycle management of therapeutic drugs and biologics. Most recently, Dr. Potts served as Senior Vice President of Regulatory Affairs at Trius Therapeutics until its acquisition by Cubist Pharmaceuticals in September 2013. Previously, she served as Senior Director, Regulatory Policy at Allergan, where she was responsible for global regulatory strategy and policy. Prior to that, Dr. Potts held various strategic positions at Isis Pharmaceuticals, Pfizer and Agouron Pharmaceuticals. She began her career as a post-doctoral fellow at the Center for Disease Control, Division of HIV/AIDS, and subsequently became a Senior Research Scientist in Infectious Disease at Searle. Dr. Potts received a bachelor's degree in Biology from Smith College and a Ph.D. in Microbiology and Immunology from Emory University.
Richard Ghalie, MD
Senior Vice President, Clinical Development
Dr. Ghalie was appointed as Senior Vice President, Clinical Development in March 2016. He is a hematologist and oncologist with more than 20 years of drug development experience at public and private companies. Dr. Ghalie has held several executive positions in the pharmaceutical industry, including serving as Chief Medical Officer at Denovo BioPharma, HemaQuest Pharmaceuticals, Novalar Pharmaceuticals and Favrille, and previously as Vice President at Ligand Pharmaceuticals and NeoRx. He was the medical lead of teams that successfully filed NDAs and MAAs resulting in the approval of four new indications. Previously, he served as Medical Director of the Bone Marrow Transplant Center of Rush University Medical Center. Dr. Ghalie holds a medical degree from the French School of Medicine in Lebanon, a MS from the University Paris XI and a MBA from the University of Washington in Seattle. He has authored or co-authored more than 125 manuscripts, book chapters and scientific publications.
Ofir Moreno, PhD
Vice President, Research & Development
Dr. Moreno joined MEI Pharma as Vice President, Pre-Clinical Research in September 2010 and was appointed Vice President, Research & Development in July 2012. During the span, he was instrumental in advancing two of the Company's pre-clinical isoflavone-based drug candidates through investigational new drug-enabling studies and into clinical trials. Dr. Moreno has nearly 20 years of experience in the pharmaceutical industry, including positions of increasing responsibility at Merck, Amgen and Corvas International (acquired by Dendreon). From August 2003 to November 2007, he served as Senior Director of Chemistry at Dendreon, where he was responsible for designing and implementing the company's small-molecule research and development platform with a strategic emphasis on outsourcing. Dr. Moreno earned his bachelor's degree in Biology and Chemistry from Cornell University and his Ph.D. in Organic Chemistry from Harvard University.
David A. Walsey, J.D., LL.M.
Vice President, Investor Relations & Corporate Communications
Mr. Walsey joined MEI Pharma as Vice President of Investor Relations and Corporate Communications in February 2018, bringing with him nearly 20 years of experience leading communications initiatives for public biotech companies. He has led investor relations and corporate communications programs at Alder Biopharmaceuticals, Optimer Pharmaceuticals, Sarepta Therapeutics (f/n/a AVI BioPharma), Arena Pharmaceuticals and Maxim Pharmaceuticals. He also has agency experience developing communications strategy and programs for biotechnology clients, having held senior positions at W20, Ruth Group and Noonan Russo. He began his career as an attorney in private practice in New York City. Mr. Walsey holds an LL.M. in Taxation from the New York University School of Law, a J.D. from Brooklyn Law School, and a B.A. from Franklin and Marshall College.